© Abalos Therapeutics 2019

News & Events

News

Stay up to date on the latest company news:
4 November 2025

Abalos Therapeutics to Present Preclinical Data Highlighting Potent, Synergistic Effects of ABX-001 in Combination with Bispecific T-cell Engagers at SITC 2025

Read full Press Release here

23 October 2025

Abalos Therapeutics Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid Tumors

Read full Press Release here

14 October 2025

Abalos Therapeutics Publishes in Cell Reports Medicine Validating ABX-001's Potential to Overcome Cancer Immunotherapy Hurdles

Read full Press Release here

09 October 2024

Abalos Therapeutics Appoints Gerben Moolhuizen as Chief Executive Officer

Read full Press Release here

18 March 2024

Abalos selected for funding project by KMU-innovativ, an initiative from Germany‘s Federal Ministry of Education and Research (BMBF)

Find more info on the KMU-i support here

18 October 2022

Abalos Therapeutics Appoints Thomas Bogenrieder as Chief Medical Officer

Read full Press Release here

12 August 2022

Abalos Therapeutics---arenaviruses take on cancer

Read the Nature Biotech article here

14 October 2021

Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million

Read full Press Release here

05 February 2020

Abalos Therapeutics Expands Leadership Team with Drug Development and Viral Therapy Manufacturing Experts

Read full Press Release here

15 October 2019

Abalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer

Read full Press Release here

Events

Want to get in touch with the Abalos Therapeutics Team? Meet us at the following events:
February 10-12, 2026

IO360° Summit 2026

Location: Boston, USA

Participant: Gerben Moolhuizen, CEO

Event website

March 4-5, 2026

19th Annual European Life Sciences CEO Forum

Location: Zurich, Switzerland

Participant: Gerben Moolhuizen, CEO

Event website